Basic Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Mar 15, 2024; 15(3): 488-501
Published online Mar 15, 2024. doi: 10.4239/wjd.v15.i3.488
MicroRNA-630 alleviates inflammatory reactions in rats with diabetic kidney disease by targeting toll-like receptor 4
Qi-Shun Wu, Dan-Na Zheng, Cheng Ji, Hui Qian, Juan Jin, Qiang He
Qi-Shun Wu, Dan-Na Zheng, Qiang He, Graduate School, Medical College of Soochow University, Suzhou 215006, Jiangsu Province, China
Qi-Shun Wu, Dan-Na Zheng, Qiang He, Department of Nephrology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou 314408, Zhejiang Province, China
Qi-Shun Wu, Department of Nephrology, Affiliated Hospital of Jiangsu University, Zhenjiang 212001, Jiangsu Province, China
Dan-Na Zheng, Department of Nephrology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou 314408, Zhejiang Province, China
Cheng Ji, Hui Qian, Molecular Inspection Laboratory, School of Medicine, Jiangsu University, Zhenjiang 212000, Jiangsu Province, China
Juan Jin, Qiang He, Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou 310060, Zhejiang Province, China
Author contributions: Wu QS conceived and designed the experiments. Wu QS and Zheng DN performed the experiments, analysed the data, and prepared all the figures; Ji C, Qian H, Jin J, and He Q provided technical support; Wu QS wrote the manuscript; and all authors contributed to the article and approved the submitted version.
Supported by the Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China, No. LHDMZ22H050001; the Construction of Key Projects by Zhejiang Provincial Ministry, No. WKJ-ZJ-2302; the Zhejiang Province Chinese Medicine Modernization Program, No. 2020ZX001; the Key Project of Scientific Research Foundation of Chinese Medicine, No. 2022ZZ002; the “Pioneer” and “LeadingGoose” R&D Program of Zhejiang, No. 2022C03118 and 2023C03075; and the Key Project of Basic Scientific Research Operating Funds of Hangzhou Medical College, No. KYZD202002.
Institutional review board statement: This study did not involve human experimentation.
Institutional animal care and use committee statement: The study was reviewed and approved by the Ethics Committee of the Laboratory Animal of Jiangsu University Institutional Review Board (Approval No. UJS-IACUC-AP-2022081615).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qiang He, MD, Chief Physician, Professor, Graduate School, Medical College of Soochow University, No. 1 Shizi Street, Gusu District, Suzhou 215006, Jiangsu Province, China. strong_he@163.com
Received: August 31, 2023
Peer-review started: August 31, 2023
First decision: December 25, 2023
Revised: January 6, 2024
Accepted: January 29, 2024
Article in press: January 29, 2024
Published online: March 15, 2024
Core Tip

Core Tip: This study revealed that microRNA-630 (miR-630) expression in the renal tissue was significantly lower in diabetic kidney disease (DKD) rats than in normal rats. The miR-630 alleviates renal injury and inflammatory reactions in DKD rats by targeting toll-like receptor 4. Our findings provide new insights into the pathogenesis of DKD indicating that miR-630 may be a potential noninvasive biomarker for diagnosing and predicting the prognosis of DKD.